Author:
Doshi Bhavya S.,Gangadharan Bagirath,Doering Christopher B.,Meeks Shannon L.
Publisher
Public Library of Science (PLoS)
Reference28 articles.
1. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;GL Bray;Blood,1994
2. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products;W Kreuz;Seminars in thrombosis and hemostasis,2002
3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;JM Lusher;The New England journal of medicine,1993
4. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia;JM Lusher,2003
5. Treatment of the bleeding inhibitor patient;J Astermark;Seminars in thrombosis and hemostasis,2003
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献